Business Wire

MA-EDB

9.12.2021 15:02:04 CET | Business Wire | Press release

Share
EDB 14 Supercharges PostgreSQL for Mission-critical Applications

EDB , an open source innovator and the leading contributor to PostgreSQL®, announced today the worldwide immediate availability of EDB 14, its premiere PostgreSQL platform. EDB® 14 adds critical enterprise capabilities, including extreme high availability and multi-master replication, which are necessary for running today’s mission-critical applications, whether high-speed transactional systems in financial services or geo-distributed analytical systems in retail. Further improvements to EDB’s powerful Oracle database compatibility technology enable even smoother migration, which is essential for the growing number of organizations moving to the cloud.

“Postgres is the fastest growing database platform worldwide with rapid adoption by developers and enterprises," Marc Linster, CTO, EDB. "With EDB 14, we've pushed Postgres even further to support our customers’ most demanding workloads and help them migrate faster at a lower total cost of ownership. This release offers even more incentive for businesses to move away from traditional databases and get onto Postgres now, or get more from it if they’re already there."

EDB 14 highlights

With the largest team of PostgreSQL engineers of any other software vendor, EDB continues to strengthen PostgreSQL to help enterprises do more and go faster. Highlights include:

  • Extreme high availability : Postgres-BDR®, a component of the EDB 14 release, allows customers to run PostgreSQL with 99.999% availability through its innovative multi-master replication capability, a feature no other PostgreSQL database offers. Multi-master replication allows customers to operate their PostgreSQL databases in “Always On” architectures with zero downtime updates and upgrades, which is critical for keeping their databases running optimally and securely.
  • Enhanced Oracle database compatibility : EDB Postgres Advanced ServerTM adds features that further improve compatibility with Oracle database technology. This capability is vital for customers looking to move applications or data from Oracle database to PostgreSQL and benefit from its superior usability and reduced operational and licensing costs.
  • Improved DevOps for PostgreSQL : EDB’s Cloud Native PostgreSQL, another component of EDB 14, helps Kubernetes users take full advantage of PostgreSQL as their database of choice. This latest version of Cloud Native PostgreSQL provides connection pooling to enable workloads with many concurrent connections to run in Kubernetes, supporting applications with even higher user demands than before.
  • Deployment flexibility : PostgreSQL customers can deploy EDB 14 in any manner, including using EDB’s BigAnimalTM , the first fully managed PostgreSQL database in the cloud with compatibility for Oracle database technology, or self-manage their database on premises.
  • Choice of PostgreSQL distributions : The EDB 14 platform has been tested with PostgreSQL 14 and EDB Postgres Advanced Server 14, enabling customers to choose between PostgreSQL distributions and tools, including open source, EDB, or a combination.

To learn more about EDB 14, visit the EDB blog . For details about BigAnimal and to sign up for a free trial, visit www.BigAnimal.com .

About EDB

PostgreSQL is increasingly the database of choice for organizations looking to boost innovation and accelerate business. EDB’s enterprise-class software extends PostgreSQL, helping our customers get the most out of it both on premises and in the cloud. And our 24x7 global support, professional services, and training help our customers control risk, manage costs, and scale efficiently. With 16 offices worldwide, EDB serves over 5,000 customers, including leading financial services, government, media and communications, and information technology organizations. To learn about PostgreSQL for people, teams, and enterprises, visit EDBpostgres.com .

EnterpriseDB, EDB and Postgres Enterprise Manager are registered trademarks of EnterpriseDB Corporation. EDB Postgres is a trademark of EnterpriseDB Corporation.

Postgres, PostgreSQL, and the Slonik Logo are trademarks or registered trademarks of the PostgreSQL Community Association of Canada, and used with their permission.

Oracle, Java, and MySQL are registered trademarks of Oracle and/or its affiliates. Other names may be trademarks of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IEO and Laife Reply Join Forces to Digitalise the Biobank Through Artificial Intelligence10.2.2026 10:00:00 CET | Press release

The two partners launch “Bianca”, the first large-scale digitalisation initiative in Italy focused on histopathological samples, aimed at training AI algorithms to support pathologists’ diagnostic activities. The Pathology Division of the European Institute of Oncology (IEO) and Laife Reply, the Reply Group company specialised in AI and Big Data solutions for the healthcare sector, have entered into a collaboration to develop Bianca, the first project in Italy aimed at creating an AI-based digital biobank designed as an integral part of clinical diagnostic practice. The initiative is part of a broader technological innovation journey that structurally integrates research and development into routine diagnostic processes in pathology, transforming the traditional histopathological sample workflow into an end-to-end digital ecosystem. The complete digitalisation of histopathological and molecular diagnostic workflows aims to make analysis more efficient, scalable and reproducible, laying

OPEX® Corporation Introduces the Velo™ Series of Premium Desktop and High Production Document Scanners10.2.2026 10:00:00 CET | Press release

OPEX® Corporation, a global leader in Next Generation Automation providing innovative solutions for warehouse, document and mail automation, has announced the launch of its Velo™ Series powered by InoTec, a new class of premium desktop and free standing high production scanners. The OPEX Velo scanners are engineered to deliver exceptional performance, reliability and image quality and offer industry-standard TWAIN/ISIS connectivity to help simplify deployment into existing capture environments. These state-of-the-art scanners are ideal for service bureaus, government agencies, healthcare providers and enterprise capture operations. “The Velo Series powered by InoTec introduces an entirely new class of scanners to the OPEX portfolio, expanding the options available to both our current customers and organizations considering OPEX for the first time,” said Dann Worrell, President, Document and Mail Automation, OPEX. “By broadening our offerings, we can better align the right solution with

New ZOLL Zenix Monitor/Defibrillator Receives MDR Approval10.2.2026 10:00:00 CET | Press release

ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that Zenix®, the company’s most clinically advanced and easy-to-use professional monitor/defibrillator, is approved under the European Union (EU) Medical Device Regulation 2017/745, commonly referred to as EU MDR. The Zenix monitor/defibrillator is a groundbreaking device that redefines efficiency, clarity, and intelligence in both EMS and hospital settings. Built from years of feedback from customers, Zenix combines intuitive design with powerful functionality to enhance patient care and automate workflows for ease-of-use. Featuring a large, durable touchscreen, Zenix provides critical information when it’s needed. With on-the-fly customization, healthcare professionals can make real-time adjustments, helping them stay in control during high-pressure situations. Equipped with ZOLL’s innovative Real BVM Help® and exclusive Real CPR Help® technology, Zenix gives healthcare pro

Expereo Elevates expereoOne with New Digital Case Management Capabilities, Delivering Faster, Clearer and More Predictable Service Resolution10.2.2026 10:00:00 CET | Press release

Expereo is redefining what’s possible for global enterprises at CiscoLive Amsterdam with the launch of its enhanced Digital Case Management (DCM) capability in expereoOne. As the world-leading managed Network as a Service (NaaS) provider, Expereo is putting customers firmly in control - slashing resolution times, cutting through operational noise and ensuring everyone is aligned every step of the way. With DCM, service issues are no longer bottlenecks: instead, enterprises experience swift, transparent outcomes, with every stakeholder empowered through a single, real-time view of progress. DCM is designed around a simple objective: enable enterprises to resolve issues faster, with greater clarity and full control, through a fully digital, software-first workflow inside expereoOne. Customers can create, manage and track cases end-to-end within a single platform, ensuring predictable, consistent and aligned service experiences across their global network footprint. Unified, digital-first

U.S. Food and Drug Administration Accepts New Drug Application and Grants Priority Review for Takeda’s Oveporexton (TAK-861) as a Potential First-in-Class Therapy for Narcolepsy Type 110.2.2026 09:15:00 CET | Press release

This FDA Acceptance is a Milestone for People Living with Narcolepsy Type 1 Who Need New and Different Treatment OptionsOveporexton is an Orexin Agonist Designed to Restore Orexin Signaling and Address the Underlying Orexin Deficiency that Causes Narcolepsy Type 1The Prescription Drug User Fee Act (PDUFA) Target Action Date is the Third Quarter of this Calendar Year Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) accepted its New Drug Application (NDA) and granted Priority Review for oveporexton (TAK-861) for the treatment of narcolepsy type 1 (NT1). Oveporexton is an investigational oral orexin receptor 2 (OX2R)-selective agonist designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date in the third quarter of this calendar year. Takeda remains on track to potentially bring the first approved orexin agonist treatment to people living

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye